Altimmune, Inc. logo

Altimmune, Inc.

Late clinical-stage biotech working to improve the lives of those living with serious liver diseases

87 employees · est. 1997 · Gaithersburg, United States

VS
Intercept Pharmaceuticals logo

Intercept Pharmaceuticals

Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.

376 employees · est. 2002 · Morristown, United States

Altimmune, Inc. is the older company (1997 vs 2002); Intercept Pharmaceuticals is the larger of the two.

Side-by-Side Comparison

Altimmune, Inc. Intercept Pharmaceuticals
Founded
1997 older 2002
Headquarters
Gaithersburg, United States Morristown, United States
Employees
87 376 larger
Industry
Biotechnology Biotechnology, Health Care, Pharmaceutical
Funding Stage
IPO Post Ipo Debt
Total Funding
$276.40M $970.05M
Funding Rounds
8 8
Services
development of peptide-based therapeutics, clinical stage research, drug development for liver diseases Not tracked yet
Target Customers
patients with metabolic dysfunction-associated steatohepatitis, patients with alcohol use disorder, patients with alcohol-associated liver disease, healthcare providers, biopharmaceutical investors Not tracked yet
Taxonomy
Biopharmaceuticals, Liver Diseases, Clinical-Stage, MASH Therapy, AUD Treatment, ALD Therapy, Glucagon Receptor, GLP-1 Receptor, Dual-Action Therapy, Metabolic Dysfunction, Steatohepatitis, Alcohol Use Disorder, Liver Health Biopharmaceutical, Liver Diseases, Rare Diseases, Drug Development, Therapeutics, Chronic Autoimmune Liver Diseases, Small Molecule Drugs, Fibrotic Diseases, Metabolic Diseases, Bile Acid Receptors, Chronic Liver Diseases, Non-viral Liver Diseases, Innovation
Website
altimmune.com interceptpharma.com
Altimmune, Inc. logo

About Altimmune, Inc.

Altimmune, Inc., founded in 1997, is a promising player in the biopharmaceutical sector, carving a niche in the treatment of liver-related diseases. Describing themselves as a "Late clinical-stage biotech working to improve the lives of those living with serious liver diseases," they focus on develo...

Intercept Pharmaceuticals logo

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, founded in 2002, is a biopharmaceutical company focused on developing novel therapeutics to treat rare and serious liver diseases such as primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). The company's last investment of $447.70M in Post-IPO...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Altimmune, Inc. and Intercept Pharmaceuticals — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Altimmune, Inc. and Intercept Pharmaceutic... — by email.

Frequently Asked Questions

Altimmune, Inc. — Late clinical-stage biotech working to improve the lives of those living with serious liver diseases. Intercept Pharmaceuticals — Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Altimmune, Inc. has raised $276.40M while Intercept Pharmaceuticals has raised $970.05M.
Altimmune, Inc. and Intercept Pharmaceuticals operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Altimmune, Inc. with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy